Clinical trials: Docosahexaenoic Acid
Major Depression, Cancer
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions…
- Conditions
- Major Depression, Cancer, Diabetes, Cardiovascular Diseases
- Trial name
- NCT01803711
- Testing
- Desvenlafaxine, Omega 3 Fatty acids
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UConn Health
Familial Adenomatous Polyposis Coli, FAP
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
This purpose of this study is to investigate whether the number and size of rectal polyps can be reduced in patients with Familial Adenomatous Polyposis (FAP) by using a highly-purified form of a naturally occurring substance…
- Trial name
- NCT00510692
- Testing
- Eicosapentanoic Acid (EPA), Endoscopy, Biopsies taken
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- S.L.A. Pharma AG
Epilepsy
Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures
The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify cardiac risk factors in people with epilepsy.
- Trial name
- FOS (NCT00871377)
- Testing
- High Dose Fish Oil, Low Dose Fish Oil
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Age-related Macular Degeneration, Cataract
Age-Related Eye Disease Study 2 (AREDS2)
Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration…
- Trial name
- AREDS2 (NCT00345176)
- Testing
- Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
- Where
- 91 sites in United States
- Volunteers
- 4,203 people
- Sponsor
- National Eye Institute (NEI)
COVID-19 Disease
Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults
A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.
- Trial name
- RESOLUTION (NCT04417257)
- Testing
- LAU-7b
- Where
- 29 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Obesity, Inflammation
Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment
Comparative, randomized, placebo-controlled, single-centre, single-blind clinical trial to assess the effectiveness of providing additional DHA omega-3 fatty acids supplements to increase the levels of pro-resolving and…
- Trial name
- NCT01865448
- Testing
- Omega-3 DHA
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Protein Supplies SL
Healthy
Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids
Background: As the main alternative fuel to glucose for the brain, increased plasma ketones could potentially help compensate for brain glucose hypometabolism occurring during aging.
- Trial name
- NCT02410161
- Testing
- alpha-linolenic acid-rich supplement
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Cancer Cachexia
A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia
The data collected through this pilot study will allow us to increase our understanding of cancer cachexia and the effect of Eicosapentaenoic Acid (EPA) on cancer cachexia.
- Trial name
- NCT00815685
- Testing
- Eicosapentaenoic Acid
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hypertriglyceridemia
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.
- Trial name
- MARINE (NCT01047683)
- Testing
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
- Where
- 60 sites in United States, Denmark and 9 more
- Volunteers
- 229 people
- Sponsor
- Amarin Pharma Inc.
Pregnancy, Child Development
Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation
The purpose of the study is to test whether nutritional supplementation during pregnancy is associated with 1) improved maternal health during pregnancy; 2) improved infant birth and neurodevelopmental outcomes, and 3) whether…
- Trial name
- NAPS (NCT02647723)
- Testing
- DHA, Sugar pill
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)
Multicenter, randomized, double-blinded, placebo-controlled clinical trial is focused on novel treatments for non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
- Trial name
- PUVENAFLD (NCT04198805)
- Testing
- Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]
- Where
- 15 sites in United States
- Volunteers
- 205 people
- Sponsor
- Naga P. Chalasani
Healthy Volunteers
Influence of Dietary Omega-3 Fatty Acids in Various triOMEG Sausages on the HS-Omega-3 Index in Healthy Individuals
New approaches to increase eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in our diet are needed, but any new approach needs to demonstrate the bioavailability of EPA+DHA, and its safety and palatability.
- Trial name
- NCT02148835
- Testing
- Sausage: Triomeg, Sausage: Control
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Clemens von Schacky
Alzheimer's Disease
DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).
- Trial name
- DHA (NCT00440050)
- Testing
- DHA (Docosahexaenoic Acid)
- Where
- 51 sites in United States
- Volunteers
- 402 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Major Depressive Disorder, Overweight
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
This project aims to evaluate whether a dose-response relationship exists between dose of polyunsaturated fatty acids (PUFA), delivered as eicosapentaenoic acid (EPA), and change in markers of inflammation, and whether these…
- Conditions
- Major Depressive Disorder, Overweight, Inflammation
- Trial name
- NCT02553915
- Testing
- EPA 1 g/day, EPA 2 g/day, EPA 4 g/day
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Massachusetts General Hospital
Hypertriglyceridemia
Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses of an omega-3 fatty acid concentrate in a group of people who normally are not treated for high lipids.
- Trial name
- OMEGA (NCT00504309)
- Testing
- 4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Penn State University
Atherosclerosis, Low-density Lipoproteins Aggregation Susceptibility
The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism
40-70 healthy volunteers of ages 18 to 65 participate in a E-EPA-diet where 3,9 grams of E-EPA is added to their normal diet and lifestyles for a month.
- Conditions
- Atherosclerosis, Low-density Lipoproteins Aggregation Susceptibility, Low-density Lipoprotein Lipid Composition, Cardiovascular Diseases
- Trial name
- EPA&LDL (NCT04152291)
- Testing
- Ethyl-Eicosapentaenoic Acid (E-EPA)
- Where
- Finland
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Wihuri Research Institute
Mild Concussion, Brain Concussion
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions
Concussions are defined as a complex pathophysiological process affecting the brain, induced by traumatic biomechanical forces. Currently the standard of care in the treatment for concussions is cognitive and physical rest until…
- Conditions
- Mild Concussion, Brain Concussion, Cerebral Concussion
- Trial name
- NCT01814527
- Testing
- Docosahexaenoic acid
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- East Carolina University
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.
- Conditions
- Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
- Trial name
- NCT01849250
- Testing
- Docosahexaenoic Acid
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Adenoma, Colorectal Cancer
PRevention Using EPA Against coloREctal Cancer
This research study is evaluating the effect of AMR101 as a possible chemopreventive agent to reduce risk of colorectal cancer in individuals with a history of colorectal adenoma.
- Conditions
- Colorectal Adenoma, Colorectal Cancer, Endoscopic Surgery, Eicosapentaenoic Acid
- Trial name
- PREPARE (NCT04216251)
- Testing
- AMR101
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Massachusetts General Hospital
Pregnancy; Nutritional Diseases
Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation
The purpose of this study is to learn if participants in the ADORE study (NCT02626299), who took a DHA supplement during pregnancy, see favorable body fat in their infants from birth to 24 months, and if excessive or appropriate…
- Trial name
- ADORE-GAINS (NCT03310983)
- Where
- United States
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center